Neumora Therapeutics (NMRA) Current Assets (2022 - 2026)

Neumora Therapeutics has reported Current Assets for 5 years, with the latest figure at $153.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 39.8% year-over-year to $153.4 million; the trailing twelve-month figure through Mar 2026 stood at $153.4 million (down 39.8% YoY), and the FY2025 full-year result was $190.5 million, down 39.33% from the prior year.
• Current Assets for Q1 2026 stood at $153.4 million, down from $190.5 million in the prior quarter.
• The five-year high for Current Assets was $525.7 million in Q3 2023, with the low at $153.4 million in Q1 2026.
• Average Current Assets over 5 years is $324.5 million, with a median of $331.3 million recorded in 2024.
• Year-over-year, Current Assets gained 23.28% in 2023 and slumped 49.2% in 2025.
• Tracing NMRA's Current Assets over 5 years: stood at $388.0 million in 2022, then climbed by 23.28% to $478.3 million in 2023, then slumped by 34.34% to $314.1 million in 2024, then slumped by 39.33% to $190.5 million in 2025, then fell by 19.47% to $153.4 million in 2026.
• The last three Current Assets figures came in at $153.4 million (Q1 2026), $190.5 million (Q4 2025), and $177.1 million (Q3 2025), per Business Quant data.

Peer Comparison